Evidence map›Paper›PMID 30584141›Full record

ArticleJournal of Alzheimer's disease : JAD2019

Lipopolysaccharide Induced Opening of the Blood Brain Barrier on Aging 5XFAD Mouse Model.

Shawn M Barton, Vaibhav A Janve, Richard McClure, Adam Anderson, Joanne A Matsubara, John C Gore, Wellington Pham

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. The endotoxin hypothesis of Alzheimer's disease.Molecular neurodegeneration · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Mucosal Immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease.International journal of molecular sciences · 2022
    Review
  16. Review
  17. When the infectious environment meets the AD brain.Molecular neurodegeneration · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Shawn M BartonVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Vaibhav A JanveVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Richard McClureVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Adam AndersonVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Joanne A MatsubaraDepartment of Ophthalmology and Visual Sciences, The University of British Columbia, Vancouver, BC, Canada.
John C GoreVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Wellington PhamVanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA.
Vanderbilt University · USUniversity of British Columbia · CAVanderbilt Health · USVanderbilt-Ingram Cancer Center

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Multifunctional Nanoparticles for Image-Guided Vaccine Delivery in CancerR01CA160700 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHAM, WELLINGTON · 2012 to 2015
$1.3M
Multi-Excitation TIRF Microscope for Shared ResourceS10OD018075 · OD · VANDERBILT UNIVERSITY · PI WELLS, K. SAM · 2015 to 2015
$370k
NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA160700NEI NIH HHS P30 EY008126NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS T32 GM007347NIH HHS S10 OD018075
6 · The paper itself

Abstract

The development of neurotherapeutics for many neurodegenerative diseases has largely been hindered by limited pharmacologic penetration across the blood-brain barrier (BBB). Previous attempts to target and clear amyloid-β (Aβ) plaques, a key mediator of neurodegenerative changes in Alzheimer's disease (AD), have had limited clinical success due to low bioavailability in the brain because of the BBB. Here we test the effects of inducing an inflammatory response to disrupt the BBB in the 5XFAD transgenic mouse model of AD. Lipopolysaccharide (LPS), a bacterial endotoxin recognized by the innate immune system, was injected at varying doses. 24 hours later, mice were injected with either thioflavin S, a fluorescent Aβ-binding small molecule or 30 nm superparamagnetic iron oxide (SPIO) nanoparticles, both of which are unable to penetrate the BBB under normal physiologic conditions. Our results showed that when pretreated with 3.0 mg/kg LPS, thioflavin S can be found in the brain bound to Aβ plaques in aged 5XFAD transgenic mice. Following the same LPS pretreatment, SPIO nanoparticles could also be found in the brain. However, when done on wild type or young 5XFAD mice, limited SPIO was detected. Our results suggest that the BBB in aged 5XFAD mouse model is susceptible to increased permeability mediated by LPS, allowing for improved delivery of the small molecule thioflavin S to target Aβ plaques and SPIO nanoparticles, which are significantly larger than antibodies used in clinical trials for immunotherapy of AD. Although this approach demonstrated efficacy for improved delivery to the brain, LPS treatment resulted in significant weight loss even at low doses, resulting from the induced inflammatory response. These findings suggest inducing inflammation can improve delivery of small and large materials to the brain for improved therapeutic or diagnostic efficacy. However, this approach must be balanced with the risks of systemic inflammation.

Indexed as

AgingAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBenzothiazolesBiological AvailabilityBlood-Brain BarrierFerric CompoundsHumansInflammationLipopolysaccharidesMiceMice, Inbred C57BLMice, TransgenicNanoparticlesPermeabilityAmyloid beta-PeptidesBenzothiazolesFerric Compoundsferric oxideLipopolysaccharidesthioflavin TAlzheimer’s diseaseblood-brain barrierdrug deliveryiron oxide nanoparticleslipopolysaccharide

Identifiers

PMID30584141
PMCPMC9026569
OpenAlexW2906268907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.